ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.89+0.08 (+2.10%)
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
ARS Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
ARS Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -163.6%. For fiscal 2025 it was -203.3%, against 9.0% the year before. The highest annual figure on record is 9.0% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -203.3% | −212.2 |
| FY2024 | Dec 31, 2024 | 9.0% | +181225.6 |
| FY2023 | Dec 31, 2023 | -181216.7% | −178581.3 |
| FY2022 | Dec 31, 2022 | -2635.4% | −2267.8 |
| FY2021 | Dec 31, 2021 | -367.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -94.4% | +63.0 |
| Q2 FY2026 | Jun 30, 2026 | -185.2% | +100.4 |
| Q1 FY2026 | Mar 31, 2026 | -267.3% | +158.4 |
| Q4 FY2025 | Dec 31, 2025 | -147.1% | −204.8 |
| Q3 FY2025 | Sep 30, 2025 | -157.4% | +767.6 |
| Q2 FY2025 | Jun 30, 2025 | -285.6% | +2217.6 |
| Q1 FY2025 | Mar 31, 2025 | -425.7% | +173274.3 |
| Q4 FY2024 | Dec 31, 2024 | 57.7% | +74862.7 |
| Q3 FY2024 | Sep 30, 2024 | -925.0% | +2558.1 |
| Q2 FY2024 | Jun 30, 2024 | -2503.2% | −1119.6 |
| Q2 FY2023 | Jun 30, 2023 | -173700.0% | −172606.5 |
| Q1 FY2023 | Mar 31, 2023 | -74805.0% | – |
| Q3 FY2022 | Sep 30, 2022 | -3483.1% | – |
| Q2 FY2022 | Jun 30, 2022 | -1383.6% | – |
| Q1 FY2022 | Mar 31, 2022 | -1093.5% | – |
See a number that looks wrong?